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Errata
In the December 2002 issue of the Journal, in the article
entitled, “3-Methylglutaconic Aciduria Type I Is Caused
by Mutations in AUH,” by IJlst et al. (71:1463–1466),
we reported the molecular basis of 3-methylglutaconic
aciduria type I. One of the patients mentioned in our
paper was the younger of two affected brothers of healthy
nonconsanguineous Moroccan parents. He had no physi-
cal abnormalities; only his speech development was re-
tarded. In our report, mutation analysis of the patient’s
AUH gene at the cDNA level revealed a homozygous
c.589CrTnonsensemutation,whereas PCR-RFLPanaly-
sis with NdeI showed an apparent heterozygousmutation
at the genomic DNA level. Recently, we have changed
to sequence analysis at the genomic level for this dis-
order. When we reinvestigated this patient using a new
primer set (In5AUHrM13NdeI: 5′-cag gaa aca gct atg
acc CAT ATG ACC ATT AGG ACC AAC AAG TG-3′
and In4AUHf-21M13: 5′-tgt aaa acg acg gcc agt ATC
GTA GAA CTG TGA TTC TG-3′), we found homo-
zygosity for the c.589CrT nonsense mutation. More-
over, sequence analysis of the RFLP-PCR fragment (ﬁg.
3B in our report) also revealed homozygosity for this
mutation. Therefore, the apparent heterozygosity at the
genomic level reported in our original paper must have
been due to partial digestion by the restriction enzyme.
In conclusion, our data demonstrate that the c.589CrT
nonsense mutation in the Moroccan patient is homozy-
gous. We regret the error.
In the May 2003 issue of the Journal, in the article
entitled, “Average Risks of Breast and Ovarian Cancer
Associated with BRCA1 or BRCA2 Mutations De-
tected in Case Series Unselected for Family History:
A Combined Analysis of 22 Studies,” by Antoniou
et al. (72:1117–1130), CIs for the penetrance esti-
mates were stated in the abstract as follows: “The
average cumulative risks in BRCA1-mutation carri-
ers by age 70 years were 65% (95% conﬁdence in-
terval 44%–78%) for breast cancer and 39% (18%–
54%) for ovarian cancer. The corresponding estimates
for BRCA2 were 45% (31%–56%) and 11% (2.4%–
19%).”
However, this should have read: “The average
cumulative risks in BRCA1-mutation carriers by age
70 years were 65% (95% conﬁdence interval 51%–
75%) for breast cancer and 39% (22%–51%) for
ovarian cancer. The corresponding estimates for
BRCA2 were 45% (33%–54%) and 11% (4.1%–
18%).” These corrected values correspond to those in
the “Results” section of the paper.
The authors regret these errors.
